Litcius/Paper detail

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

Marius M. Hoeper, Hikmet Al‐Hiti, Raymond L. Benza, Sung‐A Chang, Paul A. Corris, J. Simon R. Gibbs, Ekkehard Grünig, Pavel Jansa, James R. Klinger, David Langleben, Vallerie V. McLaughlin, G. Meyer, Jaquelina Sonoe Ota Arakaki, Andrew J. Peacock, Tomás Pulido, Stephan Rosenkranz, Carmine Dario Vizza, Anton Vonk Noordegraaf, R.J. White, Mikyung Chang, Frank Kleinjung, Christian Meier, Karen Paraschin, Hossein Ardeschir Ghofrani, Gérald Simonneau, Horst Olschewski, Marion Delcroix, Marina Andrade‐Lima, R de Amorim Corrêac, F Figueiredo Campos, Jaquelina O. Arakaki, G. Meyer, Rogério Souza, David Langleben, Hikmet Al‐Hiti, Pavel Jansa, Søren Mellemkjær, Fabrice Bauer, David Montani, Gérald Simonneau, Daniel Drömann, H-A Ghofrani, Ekkehard Grünig, Michael Halank, Matthias Held, Marius M. Hoeper, Hans Klose, Nikolaus Kneidinger, Hanno Leuchte, Christian Opitz, Stephan Rosenkranz, Heinrike Wilkens, Hubert Wirtz, Haralampos Karvounis, Georgia Pitsiou, Stylianos E. Orfanos, Michael D’Alto, Stefano Ghio, CD Vizza, Patrizio Vitulo, T. Nakayama, Hisataka Maki, Shunsuke Tatebe, Manuel Ibarra, Tomás Pulido, Arie P.J. van Dijk, Anton Vonk Noordegraaf, Tomasz Roleder, G. Castro, MJ Loureiro, Susana Robalo-Martins, Joan Albert Barberà, M Lázaro, GM Perez-Penate, Antonio Román, C-C Cheng, C-H. Hsu, H-H Hsu, Erhan Atahan, N Mogulkoc Bishop, NG Okumus, Zeynep Pınar Önen, Chang Hj, S-A Chang, Jin Sun Lee, H-K Kim, JG Coghlan, PA Corris, Colin Church, Robin Condliffe, J. Simon R. Gibbs, AJ Peacock, Stephen J. Wort, Roblee P. Allen, Samuel A. Allen, Rana Awdish, RL Benza, Shilpa A. DeSouza, Jeremy Feldman, Shilpa Johri

2021The Lancet Respiratory Medicine161 citationsDOI

Topics & Concepts

RiociguatMedicinecGMP-specific phosphodiesterase type 5Chronic thromboembolic pulmonary hypertensionOpen labelPulmonary hypertensionRescue therapySildenafilInternal medicineRandomized controlled trialCardiologyIntensive care medicinePulmonary Hypertension Research and TreatmentsPhosphodiesterase function and regulationHeart Failure Treatment and Management
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial | Litcius